RxDoctor Payments Data

Steven Gunderson, PA

Physician Assistant · Talbott, TNNPI 1790407286

Payments from drug & device makers

$6,231in general payments, 2019–2025

Across 390 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$912
  • AstraZeneca$740
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$664
  • Otsuka America Pharmaceutical, Inc.$490
  • Axsome Therapeutics, Inc.$321
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,231 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$17,048
Medicare patients
123
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$73,578
FarxigaDapagliflozin Propanediol33$37,778
OzempicSemaglutide23$32,535
EliquisApixaban31$30,115
JardianceEmpagliflozin24$28,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$25,015
Albuterol Sulfate HfaAlbuterol Sulfate80$2,101
Omeprazole62$1,282
Cefdinir55$1,105
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav58$651
Duloxetine Hcl22$643
Levothyroxine Sodium73$579
Rosuvastatin Calcium78$563
Fluticasone Propionate41$514
Novolin RInsulin Regular, Human11$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$30$73,57860 claims
AstraZenecaFarxiga$740$37,77833 claims
Novo NordiskOzempic$912$32,53523 claims
PfizerEliquis$241$30,11531 claims
Boehringer IngelheimJardiance$163$28,97324 claims
GSKTrelegy Ellipta$179$25,01526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Talbott

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →